Your browser doesn't support javascript.
loading
Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study.
Tohi, Yoichiro; Kato, Takuma; Yokomizo, Akira; Mitsuzuka, Koji; Tomida, Ryotaro; Inokuchi, Junichi; Matsumoto, Ryuji; Saito, Toshihiro; Sasaki, Hiroshi; Inoue, Koji; Kinoshita, Hidefumi; Fukuhara, Hiroshi; Maruyama, Satoru; Sakamoto, Shinichi; Tanikawa, Toshiki; Egawa, Shin; Ichikura, Haruhiko; Abe, Takashige; Nakamura, Masaki; Kakehi, Yoshiyuki; Sugimoto, Mikio.
Affiliation
  • Tohi Y; Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan. Electronic address: yoto716yotoyoto@gmail.com.
  • Kato T; Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Yokomizo A; Division of Urology, Harasanshin Hospital, Fukuoka, Japan.
  • Mitsuzuka K; Department of Urology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
  • Tomida R; Department of Urology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
  • Inokuchi J; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Matsumoto R; Department of Renal and Genito-Urinary Surgery, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.
  • Saito T; Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan.
  • Sasaki H; Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
  • Inoue K; Department of Urology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Kinoshita H; Department of Urology and Andrology, General Medical Center, Kansai Medical University, Osaka, Japan.
  • Fukuhara H; Department of Urology, Kyorin University School of Medicine, Tokyo, Japan.
  • Maruyama S; Department of Urology, Hokkaido Cancer Center, Sapporo, Japan.
  • Sakamoto S; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Tanikawa T; Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan.
  • Egawa S; Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
  • Ichikura H; Division of Urology, Harasanshin Hospital, Fukuoka, Japan.
  • Abe T; Department of Renal and Genito-Urinary Surgery, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.
  • Nakamura M; Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Kakehi Y; Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Sugimoto M; Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Urol Oncol ; 40(2): 56.e9-56.e15, 2022 02.
Article in En | MEDLINE | ID: mdl-34112576
ABSTRACT

OBJECTIVES:

This study aimed to evaluate how health-related quality of life (HRQOL) is related to repeat protocol biopsy compliance. MATERIALS AND

METHODS:

We conducted a retrospective analysis using data from a prospective cohort in the Prostate Cancer Research International Active Surveillance (PRIAS)-JAPAN study between January 2010 and August 2019. We used the Short Form 8 Health Survey (SF-8), as patient-reported outcomes, to assess HRQOL at AS enrollment and the first year of the protocol. The physical component summary (PCS) and mental component summary (MCS) were calculated from SF-8 questionnaires. The primary outcome was the evaluation of the association of HRQOL at enrollment on the first repeat biopsy compliance. The secondary outcome was the comparison of SF-8 scores during AS, stratified by repeat protocol biopsy compliance.

RESULTS:

Of 805 patients who proceeded to the first year of the protocol, the non-compliance rate was 15% (121 patients). In the adjusted model, lower MCS at enrollment was significantly associated with the first repeat protocol biopsy non-compliance (odds ratio [OR], 2.134; 95% confidence interval [CI], 1.031-4.42; P = 0.041) but not in lower PCS (OR, 0.667; 95% CI, 0.294-1.514; P = 0.333). All subscales of SF-8 were lower in the non-compliance group than in the compliance group at any point. MCS in the non-compliance group improved over time from the time of AS enrollment (2.34 increased, P = 0.152).

CONCLUSION:

Our data suggest that lower MCS at AS enrollment using patient-reported outcomes was negatively associated with the first repeat protocol biopsy compliance. Our study may support the availability of a simple questionnaire to extract non-compliance.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Quality of Life / Biopsy Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Aspects: Patient_preference Limits: Aged / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Urol Oncol Journal subject: NEOPLASIAS / UROLOGIA Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Quality of Life / Biopsy Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Aspects: Patient_preference Limits: Aged / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Urol Oncol Journal subject: NEOPLASIAS / UROLOGIA Year: 2022 Document type: Article